SCHEMBL1065675

SCHEMBL1065675

COC(=O)c1cnc(N2CCN(Cc3ccc(C#N)cc3)CC2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR6 P46095 5/20 0.50
ALDH1A1 P00352 3/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C19 P33261 2/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
PARP1 P09874 1/20 0.47
TNK2 Q07912 1/20 0.47
TNK1 Q13470 1/20 0.47
PRKAA2 P54646 1/20 0.46
FAAH O00519 1/20 0.45
CYP2C9 P11712 3/20 0.44
TSHR P16473 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2D6 P10635 2/20 0.44
HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1066722 0.90 ALDH1A1 (0.50) GPR6ALDH1A1CYP3A4PRKAA2FAAH
SCHEMBL4804346 0.85 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AHRH3SCD
SCHEMBL12933726 0.83 PARP1 (0.45) ALDH1A1PARP1TNK2TNK1HRH3
SCHEMBL14192931 0.81 ALDH1A1 (0.48) GPR6ALDH1A1CYP11B1CYP11B2PARP1
SCHEMBL28614130 0.80 SCD (0.49) ALDH1A1PARP1TNK2TNK1PRKAA2
SCHEMBL12963252 0.79 ALDH1A1 (0.72) GPR6ALDH1A1CYP11B1CYP11B2PARP1
SCHEMBL4818519 0.76 HRH3 (0.50) HRH3SCD
SCHEMBL3159765 0.75 HRH3 (0.54) HRH3
SCHEMBL1066698 0.75 KCNH2 (0.44) GPR6ALDH1A1MAPK1HSD17B10PRKAA2
SCHEMBL23193017 0.75 OGA (0.47) ALDH1A1PARP1TNK2TNK1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
EP-1663953-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-06-07 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030705-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 GPR6 4506/4885ALDH1A1 796/4885CYP3A4 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.